Invesco Ltd. Acquires New Position in Tempus AI, Inc. $TEM

Key Points

• Invesco Ltd. recently invested approximately $337,000 in Tempus AI, Inc., acquiring 6,992 shares in the company during the first quarter.
• Tempus AI reported a revenue of $314.64 million for the last quarter, surpassing analysts' estimates, and recording a year-over-year revenue increase of 89.5%.
• Seven investment analysts have rated Tempus AI with a Buy rating, while the average price target for the stock is currently $69.50.

Invesco Ltd. acquired a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 6,992 shares of the company's stock, valued at approximately $337,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. ARK Investment Management LLC raised its position in shares of Tempus AI by 35.9% during the 1st quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock valued at $361,867,000 after purchasing an additional 1,981,755 shares during the period. Vanguard Group Inc. grew its stake in Tempus AI by 6,247.5% during the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock valued at $289,204,000 after acquiring an additional 5,900,668 shares in the last quarter. Nikko Asset Management Americas Inc. grew its stake in Tempus AI by 31.5% during the first quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock valued at $205,401,000 after acquiring an additional 1,021,460 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Tempus AI by 31.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock valued at $205,284,000 after acquiring an additional 1,016,384 shares in the last quarter. Finally, CloudAlpha Capital Management Limited Hong Kong purchased a new position in Tempus AI during the first quarter valued at $34,119,000. 24.22% of the stock is currently owned by institutional investors.

Insider Activity at Tempus AI

In other Tempus AI news, COO Ryan Fukushima sold 17,460 shares of the company's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $1,303,389.00. Following the completion of the transaction, the chief operating officer directly owned 839,180 shares in the company, valued at approximately $62,644,787. This represents a 2.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore Leonsis sold 205,847 shares of the company's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $67.66, for a total transaction of $13,927,608.02. Following the transaction, the director owned 15,511 shares of the company's stock, valued at $1,049,474.26. This represents a 92.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,108,951 shares of company stock valued at $77,660,938 in the last three months. Company insiders own 26.27% of the company's stock.

Wall Street Analysts Forecast Growth

TEM has been the subject of several research analyst reports. BTIG Research raised their target price on shares of Tempus AI from $75.00 to $85.00 and gave the company a "buy" rating in a research note on Wednesday, August 20th. Piper Sandler reissued a "neutral" rating on shares of Tempus AI in a research report on Friday, August 8th. HC Wainwright initiated coverage on shares of Tempus AI in a research report on Tuesday, September 2nd. They issued a "buy" rating and a $90.00 price objective on the stock. Morgan Stanley lifted their price objective on shares of Tempus AI from $65.00 to $68.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 12th. Finally, Needham & Company LLC reissued a "buy" rating and set a $70.00 target price on shares of Tempus AI in a research report on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $69.50.

Tempus AI Stock Performance

Shares of TEM traded up $1.50 during trading hours on Friday, hitting $79.62. The stock had a trading volume of 8,986,670 shares, compared to its average volume of 11,938,277. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54. The firm has a 50-day moving average price of $65.39 and a 200 day moving average price of $59.04. Tempus AI, Inc. has a fifty-two week low of $31.36 and a fifty-two week high of $91.45. The firm has a market capitalization of $13.83 billion, a price-to-earnings ratio of -66.91 and a beta of 5.08.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The firm had revenue of $314.64 million during the quarter, compared to analysts' expectations of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The business's revenue was up 89.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($6.86) EPS. Tempus AI has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current year.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.